Aeglea Bio Therapeutics Inc
Change company Symbol lookup
Select an option...
AGLE Aeglea Bio Therapeutics Inc
GME GameStop Corp
XELA Exela Technologies Inc
ARKK ARK Innovation ETF
NVVEW Nuvve Holding Equity Warrants Exp 19 March 2026 *W EXP 03/19/2026
BEPH Brookfield BRP Holdings (Canada) Inc
CHKP Check Point Software Technologies Ltd
FDX FedEx Corp
VLON Vallon Pharmaceuticals Inc
HCNEU Jaws Hurricane Acquisition Corp
Go

Health Care : Biotechnology |
Company profile

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company’s product candidates include pegzilarginase and AGLE-177. The Company's lead product candidate, pegzilarginase, is a recombinant human arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase one Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its AGLE-177, is a novel PEGylated, or polyethylene glycol modified, human enzyme engineered to reduce Homocystinuria.

Closing Price
$6.00
Day's Change
-0.17 (-2.76%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.21
Day's Low
5.90
Volume
(Average)
Volume:
157,454

10-day average volume:
174,612
157,454

CLASS ACTION UPDATE for PHG, SESN and SAM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

3:30 pm ET October 15, 2021 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / October 15, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

PHG Shareholders Click Here: https://www.zlk.com/pslra-1/koninklijke-philips-n-v-loss-submission-form?prid=20481&wire=1

SESN Shareholders Click Here: https://www.zlk.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=20481&wire=1

SAM Shareholders Click Here: https://www.zlk.com/pslra-1/the-boston-beer-company-inc-loss-submission-form?prid=20481&wire=1

* ADDITIONAL INFORMATION BELOW *

Image: https://www.accesswire.com/users/newswire/images/668410/Rotating-Logo.jpg

Koninklijke Philips N.V. (NYSE:PHG)

PHG Lawsuit on behalf of: investors who purchased February 25, 2020 - June 11, 2021

Lead Plaintiff Deadline : October 15, 2021

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/koninklijke-philips-n-v-loss-submission-form?prid=20481&wire=1

According to the filed complaint, during the class period, Koninklijke Philips N.V. made materially false and/or misleading statements and/or failed to disclose that: (i) Philips had deficient product manufacturing controls or procedures; (ii) as a result, the Company's Bi-Level PAP and CPAP devices and mechanical ventilators were manufactured using hazardous materials; (iii) accordingly, the Company's sales revenues from the foregoing products were unsustainable; (iv) the foregoing also subjected the Company to a substantial risk of a product recall, in addition to potential legal and/or regulatory action; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Sesen Bio, Inc. (NASDAQ:SESN)

SESN Lawsuit on behalf of: investors who purchased December 21, 2020 - August 17, 2021

Lead Plaintiff Deadline : October 18, 2021

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=20481&wire=1

According to the filed complaint, during the class period, Sesen Bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

The Boston Beer Company, Inc. (NYSE:SAM)

SAM Lawsuit on behalf of: investors who purchased April 22, 2021 - September 8, 2021

Lead Plaintiff Deadline : November 15, 2021

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/the-boston-beer-company-inc-loss-submission-form?prid=20481&wire=1

According to the filed complaint, during the class period, The Boston Beer Company, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Boston Beer's hard seltzer sales were decelerating; (2) as a result, Boston Beer was reasonably likely to incur inventory write-offs; (3) the Company was reasonably likely to incur shortfall fees payable to third party brewers; (4) as a result of the foregoing, Boston Beer's financial results would be adversely impacted; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Eduard Korsinsky, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

SOURCE: Levi & Korsinsky, LLP

View source version on accesswire.com:

https://www.accesswire.com/668410/CLASS-ACTION-UPDATE-for-PHG-SESN-and-SAM-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

comtex tracking

COMTEX_395281117/2457/2021-10-15T15:30:17

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.